MEK抑制剂与二甲双胍联合在低级别浆液性卵巢癌中的协同效应
本研究在三种低级别浆液性卵巢癌(LGSOC)细胞系中观察二甲双胍、曲美替尼或2-脱氧葡萄糖单用及联用的抗增殖作用。结果显示二甲双胍呈剂量和时间依赖性抑制所有细胞系,二甲双胍与曲美替尼仅对RAS突变细胞系显示协同抑制,二甲双胍与2-DG联用对糖酵解呈协同抑制。作者认为二甲双胍单用或与MEK及糖酵解抑制剂联用可能是LGSOC的潜在疗法。
要点
- 二甲双胍对三种LGSOC细胞系均呈剂量和时间依赖性显著抑制。
- 曲美替尼显著抑制RAS突变LGSOC细胞系,对无RAS突变细胞系无反应。
- 二甲双胍与曲美替尼仅对RAS突变细胞系显示协同抑制。
核心结论
- 二甲双胍单用或与MEK及糖酵解抑制剂联用可能是LGSOC的潜在疗法,该癌种呈惰性但化疗耐药。
研究设计与样本
- 体外研究,使用三种LGSOC细胞系(VOA1056、VOA1312和VOA5646),分别以二甲双胍、曲美替尼或2-脱氧葡萄糖(2DG)单用或与二甲双胍联用处理。
- 通过MTT法在四天期间测定增殖,western blotting测定蛋白表达,Seahorse Analyzer测定二甲双胍对糖酵解和线粒体呼吸的影响。
主要发现
- 所有LGSOC细胞系均显示二甲双胍呈剂量和时间依赖性显著抑制。
- 曲美替尼显著抑制RAS突变的LGSOC细胞系(VOA1312和VOA1056),而无RAS突变的VOA5646细胞未显示任何反应。
- 二甲双胍与曲美替尼联合对RAS突变的VOA1312和VOA1056细胞显示协同抑制,但对非RAS突变的VOA5646细胞无协同作用。
- 二甲双胍和曲美替尼增加LGSOC细胞系中磷酸化AMPK表达,联合用药表达更强;曲美替尼降低所有细胞系中42/44丝裂原活化激酶磷酸化,而二甲双胍及联合用药无显著影响。
- 2-DG显著抑制所有LGSOC细胞系的糖酵解,与二甲双胍联用显示协同抑制效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade serous ovarian cancer (LGSOC) constitutes 5-8% of epithelial ovarian cancers and is refractory to chemotherapy. We and others have shown metformin to cause significant growth inhibition in high-grade ovarian cancer both in vitro and in vivo. Here, we aimed to analyze if metformin was effective in inhibiting proliferation of LGSOC alone and in combination with MEK inhibitor. METHODS: Three LGSOC lines (VOA1056, VOA1312 and VOA5646) were treated with metformin, trametinib or 2-deoxyglucose (2DG) alone or in combination with metformin. Proliferation was measured by MTT assay over a period of four days. Protein expression was measured by western blotting. Seahorse Analyzer was used to measure effect of metformin on glycolysis and mitochondrial respiration. RESULTS: All LGSOC cell lines showed significant inhibition with metformin in a dose- and time-dependent manner. Trametinib significantly inhibited the growth of Ras mutated LGSOC lines (VOA1312 and VOA1056), while VOA5646 cells without RAS mutation did not show any response. Metformin and trametinib combination showed synergistic inhibition of RAS mutated VOA1312 and VOA1056 cells, but not for non-Ras mutated VOA5646 cells. Metformin and trametinib increased phosphorylated AMPK expression in LGSOC lines with combination showing stronger expression. Trametinib decreased 42/44 mitogen activated kinase phosphorylation in all cell lines, while metformin and combination had no significant effect. 2-DG significantly inhibited glycolysis in all LGSOC lines and combination with metformin showed synergistic inhibitory effect. CONCLUSIONS: Metformin alone or in combination with MEK and glycolytic inhibitors may be a potential therapy for LGSOC, a cancer that is indolent but chemo-resistant.
引用
- Mert I, Chhina J, Allo G, et al. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecol Oncol. 2017. PMID: 28545687. doi:10.1016/j.ygyno.2017.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。